ADMAADMA Biologics, Inc.
$10.36-35% 1Y
$10.36
$7.6052 weeks$20.38
The financials
ADMA Biologics, Inc. by the numbers
ADMA Biologics, Inc. (ADMA) reported revenue of $124M in Q2 2026 (quarter ended Jun 30, 2026), up 2.0% from the same quarter a year earlier. That came with a gross margin of 69% and net income of $38M (30% of revenue). For the full year FY2025, revenue was $510M (+20% year on year) and net income $147M. Its largest segment in Q2 2026 was ADMA Bio Manufacturing at $123M, 100% of the disclosed total, well ahead of Plasma Collection Centers at 0.0%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $124M | $122M | +2.0% |
| Gross profit | $86M | $67M | +28% |
| Operating income | $52M | $43M | +23% |
| Net income | $38M | $34M | +11% |
| Diluted EPS | $0.16 | $0.14 | +14% |
| Operating | Revenue | Share |
|---|---|---|
| ADMA Bio Manufacturing | $123M | 100% |
| Plasma Collection Centers | $30K | 0.0% |
Business segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Jun 2026Total $123.3M (+8.7%)
ADMA Bio Manufacturing grew +1.1% year on year
Segment Latestquarter on quarteryear on year
- ADMA Bio Manufacturing$123.3M$123.3Mquarter on quarter +8.7%year on year +1.1%+8.7%+1.1%
- Plasma Collection Centers$30.0K$30.0Kquarter on quarter +15%year on year n/a+15%n/a